Xie W, et al. – Researchers performed an updated meta-analysis of 14 studies to assess the efficacy and safety of aspirin for the primary prevention of cardiovascular disease. Eligible studies included randomized, controlled trials comparing aspirin with placebo or no treatment that were published up to November 1, 2018. The primary efficacy endpoint was all-cause death, with secondary endpoints including cardiovascular death, myocardial infarction, and stroke. Major bleeding, gastrointestinal bleeding, and hemorrhagic stroke comprised safety endpoints. Compared with placebo or no treatment, aspirin was linked to a lower risk of myocardial infarction. Compared with control groups, however, aspirin was no linked to a lower risk of all-cause mortality or cardiovascular mortality. With respect to safety, aspirin was associated with a higher risk of major bleeding, gastrointestinal bleeding, and hemorrhagic stroke. In addition, patients’ clinical characteristics did not greatly influence the treatment affect.